Page 2 - Roger Adsett News Today

Insmed (NASDAQ:INSM – Get Free Report) had its price objective upped by analysts at Guggenheim from $50.00 to $52.00 in a research report issued on Tuesday, FlyOnTheWall reports. Guggenheim’s price objective would indicate a potential upside of 94.47% from the stock’s current price. A number of other equities research analysts have also recently commented on […]

Panagora Asset Management Inc. increased its holdings in Insmed Incorporated (NASDAQ:INSM – Free Report) by 8.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 448,581 shares of the biopharmaceutical company’s stock after acquiring an additional 34,862 shares during the quarter. […]

StockNews.com started coverage on shares of Insmed (NASDAQ:INSM – Free Report) in a report published on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. A number of other brokerages also recently issued reports on INSM. HC Wainwright reiterated a buy rating and set a $52.00 price objective on shares of Insmed […]

Pictet Asset Management SA trimmed its holdings in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 1.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 3,930,763 shares of the biopharmaceutical company’s stock after selling 55,786 shares during the period. Pictet Asset Management SA owned approximately 2.88% […]

Morgan Stanley reaffirmed their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a report released on Friday morning, Benzinga reports. Morgan Stanley currently has a $41.00 target price on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on the company. HC Wainwright reissued a buy […]

Morgan Stanley restated their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $41.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently issued reports on the stock. StockNews.com cut shares of Insmed from […]

Insmed (NASDAQ:INSM – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.68), Briefing.com reports. The firm had revenue of $77.23 million for the quarter, compared to the consensus estimate of $70.23 million. Insmed had a […]

Insmed (NASDAQ:INSM – Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.68), Briefing.com reports. The firm had revenue of $77.23 million during the quarter, compared to analysts’ expectations of $70.23 million. Insmed had a […]

Insmed (NASDAQ:INSM – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday. Separately, Guggenheim began coverage on Insmed in a research report on Tuesday, July 25th. They set a “buy” rating and a $50.00 price objective for the […]

Insmed Incorporated (NASDAQ:INSM – Get Free Report) saw a significant increase in short interest in July. As of July 15th, there was short interest totalling 9,650,000 shares, an increase of 7.7% from the June 30th total of 8,960,000 shares. Based on an average daily volume of 989,100 shares, the days-to-cover ratio is currently 9.8 days. […]